CASE REPORT

Case Report: Pulmonary Kaposi Sarcoma in a non-HIV patient

[v1; peer review: 2 approved]

Arber Kodra, Maciej Walczyszyn, Craig Grossman, Daniel Zapata, Tarak Rambhatla, Bushra Mina

Department of Internal Medicine, Lenox Hill Hospital, New York, NY, 10065, USA

Abstract

Kaposi Sarcoma (KS) is an angioproliferative tumor associated with human herpes virus 8 (HHV-8). Often known as one of the acquired immunodeficiency syndrome (AIDS)-defining skin diseases, pulmonary involvement in KS has only been discussed in a handful of case reports, rarely in a non-HIV patient. Herein we report the case of a 77 year-old- male who presented with a 6-week history of progressive dyspnea on exertion accompanied by productive cough of yellow sputum and intermittent hemoptysis. His past medical history was significant for Non-Hodgkin's Follicular B-Cell Lymphoma (NHL). Patient also had biopsy-confirmed cutaneous KS. His physical exam was notable for a 2cm firm, non-tender, mobile right submandibular lymph node. Lungs were clear to auscultation. He had multiple violet non-tender skin lesions localized to the lower extremities. CT scan of the chest showed numerous nodular opacities and small pleural effusions in both lungs. A thoracenthesis was performed, showing sero-sanguineous exudative effusions. Histopathology failed to demonstrate malignant cells or lymphoma. A subsequent bronchoscopy revealed diffusely hyperemic, swollen mucosa of the lower airways with mucopurulent secretions. Bronchoalveolar lavage PCR for HHV-8 showed 5800 DNA copies/mL. It was believed that his pulmonary symptoms were likely due to disseminated KS. This case illustrates the potential for significant lung injury from KS. It also demonstrates the use of PCR for HHV-8 to diagnose KS in a bronchoalveolar lavage sample in a case when bronchoscopic biopsy was not safe. Furthermore, this case is unique in that the patient did not match the typical KS subgroups as HIV infection and other immune disorders were ruled out. Recognition of this syndrome is critical to the institution of appropriate therapy. As such, this case should be of interest to a broad readership across internal medicine including the specialties of Pulmonology and Critical Care.

Keywords

Kaposi Sarcoma, Lymphoma, Pulmonary, Bronchoscopy
Case report

The patient was a 77 year-old Hispanic male who initially presented to the emergency room with a 6-week history of progressive dyspnea on exertion, cough productive of yellow sputum, intermittent hemoptysis, worsening fatigue and weight loss of 10 lbs. On admission, he denied fever, chills, chest pain, sick contacts, recent travel, or tuberculosis exposure and history. His past medical history was significant for Non-Hodgkin follicular B cell lymphoma (NHL) diagnosed in 1997, treated with Rituximab, Cyclophosphamide, Hydroxydaunorubicin, Oncovin and Prednisone (RCHOP) three times. Last treatment was completed 1 year prior to presentation. He also had biopsy-confirmed cutaneous Kaposi’s Sarcoma (KS), identified within the same year of presentation, treated with pegylated liposomal doxorubicin 20 mg/m^2 once every 21 days for two cycles.

On admission, he had a low grade fever and was tachycardic. His physical exam was remarkable for a 2 cm firm, non-tender, mobile right submandibular lymph node. Lungs were clear to auscultation bilaterally. He was grossly anasaric with 4 (+) pitting edema of the lower extremities. He also had multiple violet, non-tender skin lesions localized to the lower extremities, mainly around the medial aspect of his ankles and anterior thighs bilaterally.

His labs revealed a normal cardiac panel, a white blood cell (WBC) count of 8,100/mm^3 with no leukocytosis. Manual differentiation of the white blood cells showed 28% neutrophils, 48% lymphocytes, 17% monocytes and 5% eosinophils. Urinalysis and urine culture were negative for infections. Blood cultures were positive for Streptococcus pneumoniae.

A chest X-ray done on admission showed a right lung consolidation consistent with pneumonia thus the patient was started on empiric vancomycin 1gm every 12 hours and piperacillin-tazobactam 4.5gm every 8 hours for a duration of 8 days. A computerized axial tomographic (CT) scan of the chest, abdomen and pelvis, showed numerous nodular opacities throughout each lung which were suspected to be consistent with KS as well as small pleural effusions in both lungs (Figure 1).

Despite completing a course of antibiotics for pneumonia, his symptoms did not improve. A follow-up CT scan of the chest demonstrated that the bilateral pleural effusions had worsened (Figure 2). Patient underwent a thoracentesis of the larger effusion in the right lung which showed a sero-sanguineous and exudative fluid based on chemistry analysis. Histopathology failed to demonstrate malignant cells.

A bronchoscopy was also performed, revealing diffusely hyperemic and edematous mucosa of the lower airways with mucopurulent secretions (Figure 3). Biopsy was not performed at this time given concern for endobronchial bleeding. Bronchoalveolar lavage (BAL) stains and cultures were negative for bacteria, fungi or acid fast bacilli. Pneumocystis jiroveci PCR and fluid cytology were also negative but PCR for HHV-8 showed 5800 DNA copies/mL. The patient had a HIV p24 rapid antigen test done which was negative.

After two weeks of supportive treatment, the patient’s symptoms began to improve. He continued to have numerous indurated confluent lesions on his body and face consistent with KS. His pulmonary symptoms were thought to be due to disseminated KS. Following...
significant discussions with the patient and his family regarding the poor prognosis of his disease, he decided not to undergo any further antineoplastic treatments and eventually was discharged home with hospice.

**Discussion of diagnosis**

Kaposi Sarcoma (KS) is an angioproliferative tumor associated with human herpes virus 8 (HHV-8)\(^{11}\). It is one of the AIDS-defining skin diseases and is strongly linked to male homosexual behavior\(^{5}\). Four clinical variants of KS have been described: classic, African, iatrogenic and AIDS-related\(^{6}-^{10}\). The classic variant mainly affects elderly men of Eastern European Jewish and Mediterranean origin\(^{1,11}\). The African, or endemic type, affects primarily men in the 4th decade of life in East and Central Africa\(^{12}\). Its clinical presentation is similar to the classic form but with a more aggressive variant that responds poorly to conventional treatment\(^{13}\). The third variant, iatrogenic KS, is related to chronic immunosuppressive drugs used in organ-transplant recipients or cancer patients\(^{5}-^{10}\). This variant tends to be more aggressive, involving lymph nodes, mucosa and visceral organs. AIDS-related KS is an aggressive epidemic form that commonly affects patients with immunosuppression from AIDS\(^{5}\). Pulmonary involvement in KS has only been discussed in a handful of case reports, very few of which were in non-HIV patients\(^{11}-^{16}\). This is likely due to the lack of published evidence of KS in general, as well as the presence of multiple co-morbidities in most patients which may mask clear identification of pulmonary KS. In most cases, it occurs in conjunction with more extensive mucocutaneous disease\(^{11}-^{16}\). Unique manifestations that distinguish KS from other pathologic processes in the lungs have not been identified. The most common characteristics of pulmonary KS include peri-broncho-vascular and nodular opacities, thickened interlobular septa and pleural effusions\(^{17-21}\).

Signs and symptoms such as shortness of breath, hypoxemia, and dry cough are common in pulmonary KS. Hemoptysis, fever, chest pain and respiratory failure can also occur. Additionally, enlarged mediastinal lymph nodes are frequently seen in patients with this disease\(^{16}-^{21}\).

The diagnosis of pulmonary involvement in KS can often be made by a combination of clinical, radiographic and laboratory findings, in conjunction with results of a transbronchial biopsy\(^{21,22}\). Radiographic findings in pulmonary KS are varied and include segregated pulmonary nodules, pleural effusions, and hilar or mediastinal lymphadenopathy, all of which were also evident in our patient\(^{25-25}\). Several polymerase chain reaction (PCR) assays employing primers unique for HHV-8 have been described\(^{26-27}\). HHV-8 DNA can be identified using PCR in biopsies of KS, including AIDS-associated KS, classic KS, and endemic KS. Studies have also shown that HHV-8 DNA can be detected in the BAL of patients with pulmonary KS, as was evident in our case\(^{26-30}\).

Our patient did not match the typical subgroups as HIV infection and other immune disorders were ruled out. Furthermore, it has been shown that KS, in non-HIV patients, clinically resembles classic KS but occurs at a younger age, is limited to the skin, and is associated with a good prognosis\(^{5}\). Our patient, however, demonstrated both dermatologic and pulmonary manifestations suggesting a disseminated and aggressive form of the disease.

**Treatment and management**

The published literature on the treatment of KS consists mostly of retrospective series and case reports\(^{11-33}\). At the time of this case report, we are aware of only a few prospectively randomized trials to date that compare different treatments for KS, most of which were for AIDS-related KS\(^{29-33}\). This is likely due to the lack of published evidence of the disease and the presence of co-morbidities in most patients, which may limit treatment options such as in our case.

Currently, antiretroviral therapy (ART) is the first-line therapy for pulmonary KS as it is often seen in patients with HIV/AIDS\(^{11-33}\). The first-line treatment for KS in patients with CD4 counts greater than 350 cells/μL is still unclear and treatment has generally been palliative in nature.

Only systemic treatments, including chemotherapy and immunomodulators, have shown potential to cause regression in all sites of disease\(^{16-18}\). These include pegylated liposomal doxorubicin, vinblastine, alone or in combination with bleomycin, paclitaxel, oral etoposide, vinorelbine, gemcitabine and the immunomodulator recombinant interferon alfa (IFNa). Overall response rates for all of these therapies have been reported to be high and the treatments are generally well tolerated, even in the elderly population. Only one randomized trial has been conducted in which two different systemic therapies, etoposide and vinblastine, were compared in non-AIDS related KS\(^{30}\). That study showed no significant differences between the two treatments with regard to response rate or survival.

Despite the lack of randomized trials demonstrating superiority, most clinicians consider pegylated liposomal doxorubicin the first-line therapy of choice based on a retrospective multicenter series of patients with classic KS without evidence of HIV which showed ≥50% decrease in the number of measurable lesions and the absence of new cutaneous lesions for at least eight weeks in 71% of treated patients\(^{19}\).
Our patient received treatment with liposomal doxorubicin prior to admission resulting in improvement of his cutaneous lesions. Doxorubicin was planned to be started prior to discharge, but the patient declined further chemotherapy, electing to establish hospice care.

Radiotherapy is also an accepted treatment for all forms of KS. However, due to the tendency of new lesions to develop as well as the persistence of HHV-8, despite improvement of local lesions and symptoms, there is no consensus as to when to choose radiotherapy over systemic therapy.

Conclusion
KS in a non-immunocompromised patient is an infrequent occurrence and pulmonary involvement makes the diagnosis even more difficult as only a handful of cases in this patient population are present in the literature. Traditional measures of treatment are aimed at curbing the underlying immunosuppression, making it difficult to treat in individuals with normal immune function. Pulmonary involvement can be ascertained by a combination of clinical, radiographic and laboratory findings, in conjunction with results of a transbronchial biopsy.

References

1. Wahman A, Mehnick SL, Rhame FS, et al.: The epidemiology of classic, African, and immunosuppressed Kaposi’s sarcoma. Epidemiol Rev. 1991; 13: 178–99. PubMed Abstract
2. Chang Y, Cesarman E, Pessin MS, et al.: Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science. 1994; 266(5192): 1865–9. PubMed Abstract | Publisher Full Text
3. Dupin N, Grandadam M, Calvez V, et al.: Herpesvirus-like DNA sequences in patients with Mediterranean Kaposi’s sarcoma. Lancet. 1995; 345(8955): 761–2. PubMed Abstract | Publisher Full Text
4. Moore PS, Chang Y: Detection of herpesvirus-like DNA sequences in Kaposi’s sarcoma in patients with and without HIV infection. N Engl J Med. 1995; 332(18): 1181–5. PubMed Abstract | Publisher Full Text
5. Issovich J, Boffetta P, Franceschi S, et al.: Classic Kaposi sarcoma: epidemiology and risk factors. Cancer. 2000; 88(3): 500–17. PubMed Abstract | Publisher Full Text
6. Buonaguro FM, Tornesello ML, Beth-Giraldo E, et al.: Herpesvirus-like DNA sequences detected in endemic, classic, iatrogenic and epidemic Kaposi’s sarcoma (KS) biopsies. Int J Cancer. 1996; 65(1): 25–8. PubMed Abstract | Publisher Full Text
7. Kemény L, Gyalui R, Kiss M, et al.: Kaposi’s sarcoma-associated herpesvirus/ human herpesvirus-8: a new virus in human pathology. J Am Acad Dermatol. 1997; 37(1): 107–13. PubMed Abstract | Publisher Full Text
8. Gallo RC: Some aspects of the pathogenesis of HIV-1-associated Kaposi’s sarcoma. J Natl Cancer Inst Monogr. 1998; 1998(23): 55–7. PubMed Abstract | Publisher Full Text
9. Martin JN, Ganem DE, Osmond DH, et al.: Sexual transmission and the natural history of human herpesvirus 8 infection. N Engl J Med. 1998; 338(14): 948–54. PubMed Abstract | Publisher Full Text
10. Nasti G, Errante D, Santarossa S, et al.: A risk and benefit assessment of treatment for AIDS-related Kaposi’s sarcoma. Drug Saf. 1999; 20(5): 403–25. PubMed Abstract | Publisher Full Text
11. Koss CA, Jarlberg LG, den Boon S, et al.: A Clinical Predictor Score for 30-Day Mortality among HIV-Infected Adults Hospitalized with Pneumonia in Uganda. PLoS One. 2015; 10(5): e0126991. PubMed Abstract | Publisher Full Text | Free Full Text
12. Gabbe OF, Okechukwu CI, Dedicoat M, et al.: Treatment of severe or progressive Kaposi’s sarcoma in HIV-infected adults. Cochrane Database Syst Rev. 2014; 8: CD0012856. PubMed Abstract | Publisher Full Text | Free Full Text
13. Ozmen H, Baba D, Kacagan C, et al.: Case report: HIV negative isolated scrotal Kaposi’s sarcoma. Int J Surg Case Rep. 2014; 6(12): 1086–7. PubMed Abstract | Publisher Full Text | Free Full Text
14. Cakir FB, Cakir E, Tuzuner N, et al.: Classic kaposi sarcoma with pulmonary involvement mimicking endobronchial tuberculosis in a child. Pediatr Pulmonol. 2013; 48(3): 310–2. PubMed Abstract | Publisher Full Text
15. Hoskote SS, Patel VP: Pulmonary Kaposi sarcoma in AIDS. Mayo Clin Proc. 2012; 87(10): e77. PubMed Abstract | Publisher Full Text | Free Full Text
16. Gasparetto TD, Marchioni E, Lourenço S, et al.: Pulmonary involvement in Kaposi sarcoma: correlation between imaging and pathology. Orphanet J Rare Dis. 2009; 4: 18. PubMed Abstract | Publisher Full Text | Free Full Text
17. Joshi M, Markelova N, Palacio D, et al.: A patient with HIV, dyspnea, and multiple pulmonary nodules: pulmonary Kaposi sarcoma. Chest. 2006; 130(6): 1924–8. PubMed Abstract | Publisher Full Text
18. Pastor MA, Vasco B, Mosquera JM, et al.: [Two HHV8-related illnesses in a HIV-negative patient: Kaposi’s sarcoma and multicentric Castleman’s disease. Response to treatment with Rituximab and CHOP]. Actas Dermosifiliogr. 2006; 97(6): 385–90. PubMed Abstract | Publisher Full Text
19. Yoo DJ, Lee KH, Munderi P, et al.: Clinical and bronchoscopic findings in Ugandans with pulmonary Kaposi’s sarcoma. Korean J Intern Med. 2005; 20(4): 290–4. PubMed Abstract | Publisher Full Text | Free Full Text
20. Chakaya JM, Bi C, Ng’ang’a L, et al.: Pneumocystis carinii pneumonia in HIV/AIDS patients at an urban district hospital in Kenya. East Afr Med J. 2003; 80(1): 30–5. PubMed Abstract | Publisher Full Text
21. Kaplan LD, Hopewell PC, Jaffe H, et al.: Kaposi’s sarcoma involving the lung in patients with the acquired immunodeficiency syndrome. J Acquir Immune Defic Syndr. 1988; 1(1): 23–30. PubMed Abstract | Publisher Full Text
22. Hong A, Lee CB: Kaposi’s sarcoma: clinicopathological analysis of human immunodeficiency virus (HIV) and non-HIV associated cases. Pathol Oncol Res. 2002; 8(1): 31–5. PubMed Abstract | Publisher Full Text
23. Goddy MC, Rouse H, Brown JA, et al.: Imaging features of pulmonary Kaposi sarcoma-associated immune reconstitution syndrome. AJR Am J Roentgenol. 2007; 188(4): 956–65. PubMed Abstract | Publisher Full Text

Author contributions
AK drafted the manuscript and selected the references. MW and DZ performed the bronchoscopy and selected the images used for the manuscript. CG helped with drafting and editing the manuscript. TR participated in reviewing the current literature on the topic of the manuscript. BM assisted MW and DZ with the bronchoscopy, helped to edit the manuscript and coordinated the submission of manuscript. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Grant information
The author(s) declared that no grants were involved in supporting this work.

Acknowledgements
The authors would like to thank Mina Botros and Jesus Lanza for their critical revisions of intellectual and written content.
24. Restrepo CS, Martinez S, Lemos JA, et al.: Imaging manifestations of Kaposi sarcoma. Radiographics. 2000; 20(4): 1169–85. PubMed Abstract | Publisher Full Text

25. Restrepo CS, Ocazionez D: Kaposi’s sarcoma: imaging overview. Semin Ultrasound CT MR. 2011; 32(5): 456–69. PubMed Abstract | Publisher Full Text

26. Ramos da Silva S, Ferraz da Silva AP, Bacchi MM, et al.: KSHV genotypes A and C are more frequent in Kaposi sarcoma lesions from Brazilian patients with and without HIV infection, respectively. Cancer Lett. 2011; 301(1): 85–94. PubMed Abstract | Publisher Full Text

27. Reed JA, Nador RG, Spaulding D, et al.: Demonstration of Kaposi’s sarcoma-associated herpes virus cyclin D homolog in cutaneous Kaposi’s sarcoma by colorimetric in situ hybridization using a catalyzed signal amplification system. Blood. 1998; 91(10): 3825–32. PubMed Abstract

28. Benfield TL, Dood KK, Lundgren JD: Human herpes virus-8 DNA in bronchoalveolar lavage samples from patients with AIDS-associated pulmonary Kaposi’s sarcoma. Scand J Infect Dis. 1997; 29(1): 13–6. PubMed Abstract | Publisher Full Text

29. Tamir M, Reichenberger F, McGandy CE, et al.: Diagnosis of pulmonary Kaposi’s sarcoma by detection of human herpes virus 8 in bronchoalveolar lavage, Am J Respir Crit Care Med. 1998; 157(2): 458–63. PubMed Abstract | Publisher Full Text

30. Howard MR, Bink NS, Whitby D, et al.: Association of Kaposi’s sarcoma associated herpesvirus (KSHV) DNA in bronchoalveolar lavage fluid of HIV infected individuals with bronchoscopically diagnosed tracheobronchial Kaposi’s sarcoma. Sex Transm Infect. 1998; 74(1): 27–31. PubMed Abstract | Publisher Full Text | Free Full Text

31. Brenner B, Rakowsky E, Katz A, et al.: Tailoring treatment for classical Kaposi’s sarcoma: comprehensive clinical guidelines. Int J Oncol. 1999; 14(6): 1097–102. PubMed Abstract | Publisher Full Text

32. González-García J, Rubio García R, Antelo López A, et al.: [Pneumocystis carinii pneumonia and HIV infection: diagnosis and treatment]. Enferm Infecc Microbiol Clin. 1998; 16(Suppl 1): 36–44. PubMed Abstract

33. Goebel FD, Jablonowski H: Therapy of special HIV-associated diseases: HCV-HIV-co-infection and AIDS-related Kaposi’s sarcoma - official satellite to the 7th European Conference on Clinical Aspects and Treatment of HIV-infection, October 23, 1999 in Lisbon, Portugal. Eur J Med Res. 1999; 4(12): 507–13. PubMed Abstract

34. Martorano LM, Cannella JD, Lloyd JR: Mucocutaneous presentation of Kaposi sarcoma in an asymptomatic human immunodeficiency virus-positive man. Cutis. 2015; 95(4): E19–22. PubMed Abstract

35. Brambilla L, Labianca R, Boneschi V, et al.: Mediterranean Kaposi’s sarcoma in the elderly. A randomized study of oral etoposide versus vinblastine. Cancer. 1994; 74(10): 2873–8. PubMed Abstract | Publisher Full Text

36. Di Lorenzo G, Kreuter A, Di Trollo R, et al.: Activity and safety of pegylated liposomal doxorubicin as first-line therapy in the treatment of non-visceral classic Kaposi’s sarcoma: a multicenter study. J Invest Dermatol. 2008; 128(6): 1578–80. PubMed Abstract | Publisher Full Text

37. Northfelt DW, Deuzee BJ, Thommes JA, et al.: Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi’s sarcoma: results of a randomized phase III clinical trial. J Clin Oncol. 1998; 16(7): 2445–51. PubMed Abstract

38. Di Lorenzo G, Di Trollo R, Montesarchio V, et al.: Pegylated liposomal doxorubicin as second-line therapy in the treatment of patients with advanced classic Kaposi sarcoma: a retrospective study. Cancer. 2008; 112(5): 1147–52. PubMed Abstract | Publisher Full Text

39. Huang KM, Hsu CH, Cheng JC, et al.: Radiotherapy of classic Kaposi’s sarcoma in Taiwan, an area where classic Kaposi’s sarcoma is not prevalent. Anticancer Res. 2006; 26(6C): 4659–63. PubMed Abstract

40. Caccialanza M, Marca S, Piccinno R, et al.: Radiotherapy of classic and human immunodeficiency virus-related Kaposi’s sarcoma: results in 1482 lesions. J Eur Acad Dermatol Venereol. 2008; 22(3): 297–302. PubMed Abstract | Publisher Full Text
Open Peer Review

Current Peer Review Status: ✔️ ✔️

Version 1

Reviewer Report 12 November 2015

https://doi.org/10.5256/f1000research.7687.r11204

© 2015 Bai C. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Chunxue Bai
Department of Pulmonary Medicine, Fudan University School of Medicine, Zhongshan Hospital, Shanghai, China

Arber Kodra et al. presented a case of KS that involved the pulmonary in a HIV negative patient. This patient has past medical history of NHL and cutaneous KS. PCR for HHV-8 in BALF showed 5800 DNA copies/ml and bronchoscopy showed diffusely hyperemic and edematous mucosa of lower airways. The authors claimed that this patient’s pulmonary symptoms were likely due to disseminated KS and the useful of PCR for HHV-8 to diagnose KS in a BALF sample in a case when bronchiscopic biopsy was not safe.

1. KS is thought to originate from HHV8 infected lymphatic endothelial cells. HHV8 is recognized as an essential and necessary factor in the pathogenesis of KS. However, not all HHV-8 infected individuals will develop the disease. The authors examined PCR for HHV-8 in BALF sample; however, it will be more convincing if the author could provide pathological results to demonstrate the patient pulmonary symptoms were likely due to disseminated KS.

2. In this case, the past medical history of this patient was significant for Non-Hodgkin’s Follicular B-Cell Lymphoma. NHL may also lead to nodular opacities throughout both lungs.

3. The abnormal cells of KS form purple, red, or brown patches, plaques or tumors on the skin. It will be better if the authors could provide some pictures of cutaneous lesions.

4. It is a little puzzled that the “lung were clear to auscultation.“, whereas CT scan showed pleural effusions on both lungs.

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
This very nice case report serves to remind practitioners everywhere the Kaposi's sarcoma both occurs independently of HIV disease, and can affect organ systems other than the skin. Modern diagnostic techniques and imaging, used as described in this report, allow us to document manifestations of Kaposi's that were previously undocumented.

**Competing Interests:** No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.